Upregulation of microRNA-1303 is a potential prognostic marker of non-small cell lung cancer

Abstract

BACKGROUND:

Non-small cell lung cancer (NSCLC) is the major subtype of lung cancer, imposing a huge disease burden worldwide. MicroRNA-1303 (miR-1303) has been demonstrated to be involved in several diseases, including cancers. In this study, we aimed to investigate the role of miR-1303 in NSCLC.

METHODS:

We quantified the expression levels of miR-1303 in NSCLC tissues and cells using the qRT-PCR assay. Then the association between miR-1303 expression and clinical characteristics of patients was analyzed using the $\chi^{2}$ test. The Kaplan-Meier and multivariate Cox regression assays were used to investigate the prognostic value of miR-1303 in NSCLC. Furthermore, the functional proliferation, migration, and invasion assays were used to explore the miR-1303 functions in vitro.

RESULTS:

The expression of miR-1303 was upregulated in NSCLC tissue samples and cells. The upregulation of miR-1303 was associated with TNM stage and lymph node metastasis. The survival time of NSCLC patients with high expression of miR-1303 was shorter than those with low expression. The functional analyses revealed that overexpression of miR-1303 in H1299 and A549 cells promoted cell proliferation, migration, and invasion.

CONCLUSION:

These results suggest that miR-1303 may be a potential prognostic biomarker for NSCLC and be involved in the progression of NSCLC.

Keywords

microRNA-1303 NSCLC proliferation prognosis migration invasion

1. Introduction

Lung cancer, an aggressive tumor with high morbidity and mortality, remains the leading cause of cancer-related deaths around the world [1]. Histologically, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) are the two major types of lung cancer, in which NSCLC comprises more than 80% of all lung cancer cases [2]. The environmental tobacco smoke exposure, family history of lung cancer, and air pollution are the main risk factors for the initiation and progression of NSCLC [3, 4]. In addition, metastasis is the main factor leading to disease progression and poor prognosis of NSCLC patients [5]. In recent years, although available therapies (such as surgery, chemotherapy, and radiotherapy) for the treatment of NSCLC have been developed, the 5-year overall survival rate of patients is still less than 20%, which was not significantly improved [6]. Therefore, searching for more molecules and genes associated with the development of NSCLC is particularly important for the treatment of NSCLC.

MicroRNAs (miRNAs) are small (appreciate 21 nucleotides long), non-coding, single-stranded RNAs that negatively regulate gene expression by binding the 3’-UTR of target mRNAs [7, 8]. Abnormal expression of miRNAs has been reported in various types of diseases, including cancers, where they may function as oncogenes or suppressors [9, 10]. Moreover, a number of studies have revealed that aberrant expression of miRNAs might function as diagnostic and/or prognostic biomarkers in various tumors [11, 12]. Importantly, miRNAs play crucial roles in various biological processes, including cellular growth and proliferation, differentiation, metastasis, and apoptosis [13, 14]. In NSCLC, miR-187 [15], miR-593-5p [16], and miR-141 [17] have been reported aberrantly expressed, and acted an oncogenic or a suppressive role to regulate cell proliferation, invasion, and metastasis. Previous researches have also indicated that miR-1303 expression was involved in the development of several diseases [18, 19], including cancers, such as hepatocellular carcinoma [20] and esophageal squamous cell carcinoma [21]. A miRNA expression profiling study revealed that numerous miRNAs were differentially expressed in NSCLC tissues versus adjacent normal tissues, including miR-1303 [22]. However, the clinical significance and functional role of miR-1303 in NSCLC remain largely unknown.

In this study, we detected the miR-1303 expression levels in NSCLC tissues and adjacent normal lung tissues, as well as NSCLC cell lines and normal epithelial cells. Based on its expression and survival information, we explored the clinical prognostic value of miR-1303 in NSCLC. Furthermore, we investigated the functional role of miR-1303 in NSCLC. Our results suggest that miR-1303 might play an oncogenic role and be a potential prognostic biomarker and therapeutic target in NSCLC.

2. Materials and methods

2.1 Patients and tissue samples

The present study was approved by the Ethical Review Committee of Liaocheng People’s Hospital. All the NSCLC patients enrolled in the study signed written informed consent before tissue collection. The patients were recruited based on the following inclusion criteria: (1) All the patients did not undergo preoperative therapies (chemotherapy or radiotherapy). (2) All the cases were pathologically diagnosed as NSCLC. (3) The patients who were at early or middle stages, and those at advanced stages, whose lesion is confined to one side of the thorax and can be completely removed, or with solitary metastasis. A total of 113 paired NSCLC tissue samples and adjacent non-tumor tissue samples (approximately 5 cm away from the edge of the lung tumor) were collected from patients who received surgical resection at Liaocheng People’s Hospital during the study. These tissue specimens were immediately frozen in liquid nitrogen after resection until RNA extraction. The clinical medical records of NSCLC patients were collected and corresponding clinical characteristics were recorded in Table 1. The TNM stage of the tumors was confirmed following the 7 ${}^{\rm th}$ edition of the AJCC cancer staging manual. A 5-year follow-up survival information of patients was collected for subsequent survival analyses.

2.2 Cell culture and transfection

Human NSCLC cell lines (H1299, A549, NCI-H1650, HCC827) and immortalized bronchial epithelial cell BEAS-2B were purchased from the cell bank of Chinese Academy Sciences (Shanghai, China). All cells were cultured in DMEM medium (Gibco, NY, USA) supplemented with 10% FBS (Gibco, Grand Island, NY, USA) in a humidified incubator containing 5% at 37 ${}^{\circ}$ C.

Figure 1.

miR-1303 is upregulated in NSCLC tissue samples and cells. A. Relative expression of miR-1303 in NSCLC tissue samples and corresponding normal tissue samples. B. Expression of miR-1303 in four NSCLC cell lines and normal epithelial cell BEAS-2B. ${}^{***}P<$ 0.001.

Before transfection, NSCLC cells were seeded into 6-well plates and incubated overnight. The miR-1303 mimics, mimic negative control (mimic NC), miR-1303 inhibitors, inhibitor NC were chemically synthesized by GenePharma Co., Ltd. (Shanghai, China). Then the cells were transfected with miR-1303 mimic, miR-1303 inhibitor, or their corresponding NCs using Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA) following the manufacturer’s protocol. After 24 h transfection, further experiments were performed.

2.3 RNA isolation and quantitative reverse-transcription PCR (qRT-PCR)

The total RNA was extracted from patients’ tissue specimens and cultured cells using TRIzol reagent (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s instructions. Then RNA was reverse transcribed to cDNA using the TaqMan miRNA reverse transcription kit (Applied Biosystems, Thermo Fisher Scientific) according to the manufacturer’s instructions. Subsequently, the qRT-PCR assay was carried out using SYBR Premix Ex Taq II (TaKaRa, Dalian, China) on a 7500 Real-Time PCR System (Applied Biosystems, USA). The expression levels of miR-1303 were quantified using the 2 ${}^{-\Delta\Delta Ct}$ method and normalized to U6.

2.4 Cell proliferation assay

The cell proliferation of A549 and H1299 cells was assessed using cell counting kit-8 (CCK-8; Dojindo, Tokyo, Japan). Briefly, transfected cells were seeded into 96-well plates (4 $\times$ 10 ${}^{3}$ cells/well), and the cells were incubated for 0, 24, 48, 72 h at 37 ${}^{\circ}$ C. Then 10 $\mu$ l CCK-8 reagent was added to each well and incubated for 2 h. The absorbance value of each well was measured at 450 nm.

2.5 Cell migration and invasion assays

The migratory and invasive capabilities of A549 and H1299 cells were detected using a 24-well Transwell chamber (8 $\mu$ m pore; Corning, NY, USA). The chambers used for invasion assay were precoated with Matrigel (Corning, NY, USA), while the chamber for migration assay did not coat matrigel. Transfected cells (5 $\times$ 10 ${}^{4}$ cells/well) that resuspended in serum-free medium were added to the upper chamber of transwell plates, and the lower chambers were filled with complete medium containing 10% FBS as attractants. After 24 h of incubation, migrated or invasive cells were stained with crystal violet. The number of migrated and invasive cells was counted in five random fields under a light microscope.

Table 1
Correlation of the miR-1303 expression with clinical characteristics in NSCLC

Parameters	Cases	miR-1303 expression		$P$
	( $n=$ 113)	Low ( $n=$ 56)	High ( $n=$ 57)
Age				0.386
$\leqslant$ 60	49	22	27
$>$ 60	64	34	30
Gender				0.787
Male	66	32	34
Female	47	24	23
Tumor size				0.107
$\leqslant$ 5 cm	67	29	38
$>$ 5 cm	46	27	19
Smoking status
Non-smoker	62	33	29	0.390
Smoker	51	23	28
Differentiation				0.209
Well, moderate	66	36	30
Poor	47	20	27
Lymph node metastasis				0.007
Negative	75	44	31
Positive	38	12	26
TNM stage				0.004
I, II	74	44	30
III, IV	39	12	27

2.6 Statistical analysis

All the experiments were repeated at least three times, and all the data in the present study were expressed as mean $\pm$ SD. The SPSS software (version 20.0; IBM, Aemonk, NY, USA) statistical packages and GraphPad software (version 5.0, La Jolla, CA, USA) were used for data analyses. $\chi^{2}$ test was used to compare the association between miR-1303 expression and clinical characteristics of patients. Student’s t-test was used to determine differences between two groups. Among three or more groups, one-way ANOVA followed by Tukey’s post-hoc test was used. The Kaplan-Meier curve and multivariate Cox regression assay were used to explore the prognostic significance of miR-1303. Values were considered statistically significant when $P$ less than 0.05.

3. Results

3.1 miR-1303 is upregulated in NSCLC tissues and cells

First, the expression of miR-1303 in NSCLC tissue specimens was measured using the qRT-PCR assay. As shown in Fig. 1A, miR-1303 was significantly upregulated in NSCLC tissue specimens compared with adjacent normal tissues ( $P<$ 0.001). The distribution of TNM stage for all patients and the expression of miR-1303 in these tissues were shown in Supplementary Table 1. In addition, the expression levels of miR-1303 were also measured in NSCLC cells and normal human lung epithelial cells BEAS-2B. In Fig. 1B, miR-1303 expression was also found to be increased in NSCLC cells compared with that in BEAS-2B cells ( $P<$ 0.01). Among these NSCLC cells, A549 and H1299 cells exhibited higher miR-1303 expression levels than the other two NSCLC cells, thus, A549 and H1299 cells were used for subsequent gain/loss-of-function experiments.

Figure 2.

Kaplan-Meier method was used to analyze the 5-year survival rate of NSCLC patients with high and low expression of miR-1303. Patients with high miR-1303 expression exhibit a shorter overall survival rate than those with low miR-1303 expression (log-rank test $P=$ 0.024).

3.2 The relationship between miR-1303 expression and clinical characteristics of NSCLC patients

Based on the relative expression of miR-1303 in NSCLC tissues, we also analyzed the relationship between miR-1303 expression and clinical characteristics of NSCLC patients, and 113 NSCLC patients were separated into low miR-1303 expression group ( $n=$ 56) and high miR-1303 expression group ( $n=$ 57) according to the median level of miR-1303 expression in NSCLC tissues. Using the $\chi^{2}$ test, we observed that high miR-1303 expression in NSCLC was obviously associated with lymph node metastasis ( $P=$ 0.007) and TNM stage ( $P=$ 0.004). However, the expression of miR-1303 was not found associated with age, gender, tumor size, smoking status, and differentiation ( $P>$ 0.05, Table 1).

3.3 Increased expression of miR-1303 associates with prognosis in NSCLC

To determine whether the miR-1303 expression has the clinical prognostic significance in NSCLC, the Kaplan-Meier curve was conducted using the survival information of patients. As shown in Fig. 2, patients with high miR-1303 expression levels had a shorter overall survival time, whereas those with low miR-1303 expression exhibited longer survival time (log-rank test, $P=$ 0.024). Further analysis using multivariate Cox regression analysis revealed that miR-1303(HR $=$ 2.121, 95%CI: 1.057–4.259, $P=$ 0.034) and TNM stage (HR $=$ 1.985, 95% CI: 1.022–3.852, $P=$ 0.043) were independent prognostic indicator for NSCLC patients (Table 2).

Figure 3.

Overexpression of miR-1303 promotes cell proliferation, while inhibition of miR-1303 suppresses cell proliferation of H1299 and A549 cells, compared with untreated cells. A. miR-1303 expression was determined by qRT-PCR. miR-1303 expression in H1299 and A549 cells transfected with miR-1303 mimics or miR-1303 inhibitors. B. The CCK-8 assay was used to detect the effects of miR-1303 mimics or inhibitors on the cell proliferation of H1299 and A549 cells. ${}^{*}P<$ 0.05, ${}^{**}P<$ 0.01, ${}^{***}P<$ 0.001.

Table 2

Multivariate Cox analysis of clinical characteristics in relation to overall survival

Characteristics	Multivariate analysis
	HR	95% CI	$P$
miR-1303	2.121	1.057–4.259	0.034
Age	1.737	0.887–3.405	0.107
Gender	0.668	0.352–1.266	0.216
Tumor size	0.544	0.274–1.082	0.083
Smoking status	1.725	0.856–3.474	0.127
Differentiation	0.518	0.268–1.004	0.052
Lymph node metastasis	1.959	0.990–3.878	0.054
TNM stage	1.985	1.022–3.852	0.043

3.4 Overexpression of miR-1303 effects NSCLC cell proliferation, migration, and invasion

To study whether miR-1303 expression would affect the progression of NSCLC, subsequently, we explored the effects of miR-1303 in NSCLC by upregulating or downregulating miR-1303 expression in A549 and H1299 cells. Then qRT-PCR assay was used to confirm transfection efficiency. As expected, the expression of miR-1303 was significantly overexpressed after transfection of miR-1303 mimic in H1299 and A549 cells, while the expression of miR-1303 was significantly downregulated after transfection of miR-1303 inhibitor in H1299 and A549 cells ( $P<$ 0.001, Fig. 3A). Subsequently, CCK-8 assay revealed that overexpression of miR-1303 promoted cell proliferation, while downregulation of miR-1303 inhibited cell proliferation, compared with that in untreated cells ( $P<$ 0.05, Fig. 3B). Furthermore, transwell migration and invasion assays indicated that overexpression of miR-1303 promoted cell migration and invasion, whereas inhibition of miR-1303 suppressed cell migration and invasion of H1299 and A549 cells, compared with untreated cells ( $P<$ 0.001, Fig. 4A and B).

Figure 4.

Upregulation of miR-1303 promotes cell migration and invasion, while knockdown of miR-1303 inhibits cell migration and invasion of H1299 and A549 cells, compared with untreated cells. A. Transwell migration assay was used to detect the effects of miR-1303 on the cell migration of H1299 and A549 cells. B. Transwell invasion assay was used to detect the effects of miR-1303 on the cell invasion of H1299 and A549 cells. ${}^{***}P<$ 0.001.

4. Discussion

The development of NSCLC is a series of complex, multi-step and multi-factor process. In recent years, miRNAs have been reported that associated with the development, occurrence, and metastasis of various types of cancers [9, 23]. Moreover, miRNAs have gained growing research and considerable attention as therapeutic targets for the treatment of diseases, including cancers [24]. Thus, identifying novel markers as possible prognostic biomarkers or therapeutic targets may be helpful for improving the treatment of NSCLC.

miR-1303, located on 5q33.2, is an important miRNA that has been indicated to be aberrantly expressed in several types of diseases, including cancers, and involved in the development of several types of cancers [25, 26]. In the present study, we examined the expression of miR-1303 in NSCLC tissue samples and cell lines. The results showed that the expression of miR-1303 was significantly upregulated in NSCLC tissue samples and all the NSCLC cells, compared with corresponding normal tissue samples and BEAS-2B cells, respectively. The results suggest that miR-1303 may be a tumor suppressor in NSCLC. These results are consistent with a number of previous studies. For instance, miR-1303 was significantly overexpressed in gastric cancer tissues and cell lines [27].

Aberrantly expression of miRNAs was involved in the growth and development of cancers, which indicated the clinical potential of miRNAs as diagnostic and/or prognostic biomarkers [28, 29, 30]. For instance, miR-133b is downregulated in NSCLC, is involved in NSCLC metastasis, and may function as a biomarker for the diagnosis and prognosis of NSCLC [31]. A previous study used the metastasis-free survival rates information for analysis and demonstrated that miR-1303 was associated with metastasis-free survival in inflammatory breast cancer [26]. In this study, we used the overall survival information of NSCLC patients and further explored the potential clinical significance of miR-1303 in NSCLC. The results indicated that patients with high miR-1303 expression levels exhibited a shorter overall survival rate compared with those with low miR-1303 expression levels. Multivariate Cox regression assay revealed that miR-1303 expression was an independent prognostic predictor for NSCLC. The above results suggest that miR-1303 expression may be a novel prognostic biomarker for NSCLC.

To investigate the functional role of miR-1303 in NSCLC, gain/loss-of-function experiments were carried out to upregulate or downregulate the expression of miR-1303 in H1299 and A549 cells. The results indicated that overexpression of miR-1303 in NSCLC cells promoted the proliferative, migratory, and invasive capabilities of NSCLC cells, while downregulation of miR-1303 inhibited the proliferative, migratory, and invasive capabilities of NSCLC cells, compared with untreated cells. Previously, miR-1303 has been demonstrated to promote the proliferation, migration, and invasion of prostate cancer cells through activating the Wnt/ $\beta$ -catenin pathway by regulating DKK3 expression [32]. Another study showed that miR-1303 promoted neuroblastoma cell proliferation by targeting GSK3 $\beta$ and SFRP1 and may be a target for neuroblastoma therapy [33]. miR-1303 was significantly overexpressed in gastric cancer tissues and cell lines, and downregulation of miR-1303 could inhibit proliferation, migration, and invasion of gastric cancer cells by targeting CLDN18 [27]. Consistent with these above previous studies, miR-1303 may also play an oncogenic role in NSCLC. The previous study demonstrated that CLDN18 was downregulated in lung cancer and involved in the progression of lung cancer [34, 35]. Thus, we speculate miR-1303 may also promote cell proliferation, migration, and invasion of NSCLC cells by targeting CLDN18. Further studies would be necessary to prove our findings and define whether miR-1303 targets CLDN18 or other genes in NSCLC.

All in all, there are some limitations to the present study. The sample size in the present study is limited and the clinical prognostic significance of miR-1303 still needs to be confirmed using large scale samples. In addition, another limitation of this study is that the precise molecular mechanism of miR-1303 needs to be confirmed in future studies.

Taken together, our study demonstrated miR-1303 is upregulated in NSCLC tissues and cells, and its overexpression of miR-1303 promotes cell proliferation, migration, and invasion. NSCLC patients with high miR-1303 expression have a shorter overall survival rate than those with low miR-1303 expression. Thus, our results provide a novel insight into the prognosis and treatment of NSCLC, and miR-1303 may be associated with prognostic overall survival rates, indicating the great potential of miR-1303 as a therapeutic target for the treatment of NSCLC.

Footnotes

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary data

Supplementary Table S1

The expression of miR-1303 in NSCLC patients according to TNM stage

TNM stage	Cases No.	miR-1303 expression in tissue
I	39	1.144 $\pm$ 0.277
II	35	1.176 $\pm$ 0.301
III	36	1.368 $\pm$ 0.216
IV	3	1.429 $\pm$ 0.230

References

Torre

L.A.

Siegel

R.L.

and Jemal

, Lung cancer statistics, Adv Exp Med Biol 893 (2016), 1–19.

Guarnera

M.A.

Zhou

Fang

and Jiang

, A prediction model based on biomarkers and clinical characteristics for detection of lung cancer in pulmonary nodules, Transl Oncol 10 (2017), 40–45.

Schwartz

A.G.

and Cote

M.L.

, Epidemiology of lung cancer, Adv Exp Med Biol 893 (2016), 21–41.

Y.L.

Hsiao

C.F.

Chang

G.C.

Tsai

Y.H.

Huang

M.S.

W.C.

Chen

Y.M.

Hsin

C.W.

Chang

C.H.

Yang

P.C.

Chen

C.J.

and Hsiung

C.A.

, Risk factors for primary lung cancer among never smokers by gender in a matched case-control study, Cancer Causes Control 24 (2013), 567–576.

K.L.

Tsai

M.J.

Yang

C.J.

Chang

W.A.

Hung

J.Y.

Yen

C.J.

Shen

C.H.

Kuo

T.Y.

Lee

J.Y.

Chou

S.H.

Liu

T.C.

Chong

I.W.

and Huang

M.S.

, Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib, Lung Cancer 88 (2015), 187–194.

Allemani

Matsuda

Di Carlo

Harewood

Matz

Niksic

Bonaventure

Valkov

Johnson

C.J.

Esteve

Ogunbiyi

O.J.

Azevedo

E.S.G.

Chen

W.Q.

Eser

Engholm

Stiller

C.A.

Monnereau

Woods

R.R.

Visser

Lim

G.H.

Aitken

Weir

H.K.

Coleman

M.P.

and Group

C.W.

, Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries, Lancet 391 (2018), 1023–1075.

and Hannon

G.J.

, MicroRNAs: small RNAs with a big role in gene regulation, Nat Rev Genet 5 (2004), 522–531.

Filipowicz

Bhattacharyya

S.N.

and Sonenberg

, Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?, Nat Rev Genet 9 (2008), 102–114.

Rupaimoole

and Slack

F.J.

, MicroRNA therapeutics: towards a new era for the management of cancer and other diseases, Nat Rev Drug Discov 16 (2017), 203–222.

10.

Zarredar

Ansarin

Baradaran

Shekari

Eyvazi

Safari

and Farajnia

, Critical microRNAs in Lung Cancer: Recent Advances and Potential Applications, Anticancer Agents Med Chem 18 (2018), 1991–2005.

11.

Ning

Liu

Gao

Wei

Yang

and Zhang

, miR-155, miR-96 and miR-99a as potential diagnostic and prognostic tools for the clinical management of hepatocellular carcinoma, Oncol Lett 18 (2019), 3381–3387.

12.

Kong

Ning

Qiu

and Cao

, Clinical significance of serum miR-25 as a diagnostic and prognostic biomarker in human gastric cancer, Cancer Biomark 24 (2019), 477–483.

13.

Sur

Steele

Shi

and Ray

R.B.

, miRNA-29b Inhibits Prostate Tumor Growth and Induces Apoptosis by Increasing Bim Expression, Cells 8 (2019).

14.

Han

Huang

Yang

Zhang

Wang

Meng

Huang

Yang

Shen

and Sun

, miR-449a Is Related to Short-Term Recurrence of Hepatocellular Carcinoma and Inhibits Migration and Invasion by Targeting Notch1, Onco Targets Ther 12 (2019), 10975–10987.

15.

Liang

and Zhu

, MiR-187 suppresses non-small-cell lung cancer cell proliferation by targeting FGF9, Bioengineered 11 (2020), 70–80.

16.

Yan

Zhang

Wang

Ling

Liu

Zhu

and Zhang

, miR-593-5p inhibit cell proliferation by targeting PLK1 in non small cell lung cancer cells, Pathol Res Pract (2019), 152786.

17.

Kong

Y.J.

Tan

X.X.

Zhang

Q.J.

Zhao

and Meng

, MiR-141 promotes cell proliferation and invasion in non-small cell lung cancer by targeting KLF9, Eur Rev Med Pharmacol Sci 23 (2019), 10370–10378.

18.

Huang

Zhang

and He

, Evaluation of microRNA Expression in Patients with Herpes Zoster, Viruses 8 (2016).

19.

Song

Huang

Zheng

Wang

Jiang

Yang

Fan

Guo

Shi

Yang

Wang

Dong

and Liu

, miR-1303 regulates BBB permeability and promotes CNS lesions following CA16 infections by directly targeting MMP9, Emerg Microbes Infect 7 (2018), 155.

20.

Xiong

D.D.

Dang

Y.W.

Lin

Wen

D.Y.

R.Q.

Luo

D.Z.

Feng

Z.B.

and Chen

, A circRNA-miRNA-mRNA network identification for exploring underlying pathogenesis and therapy strategy of hepatocellular carcinoma, J Transl Med 16 (2018), 220.

21.

Okumura

Kojima

Miwa

Sekine

Hashimoto

Hojo

Nagata

and Shimada

, The expression of microRNA 574-3p as a predictor of postoperative outcome in patients with esophageal squamous cell carcinoma, World J Surg Oncol 14 (2016), 228.

22.

Yang

Sun

Liang

Xie

Huang

and Li

, Integrative analysis of microRNA and mRNA expression profiles in non-small-cell lung cancer, Cancer Gene Ther 23 (2016), 90–97.

23.

Rezaei

Mansoori

Hashemi

Z.S.

Amini

Rezaei

Karami

Mosafer

Mokhtarzadeh

and Baradaran

, microRNA-181 serves as a dual-role regulator in the development of human cancers, Free Radic Biol Med (2019).

24.

Van Roosbroeck

and Calin

G.A.

, Cancer hallmarks and MicroRNAs: The Therapeutic connection, Adv Cancer Res 135 (2017), 119–149.

25.

Wang

Wan

Yang

Niu

Zhang

Yang

Cai

Song

Zhang

C.Y.

Zhang

and Wang

, Increased serum microRNAs are closely associated with the presence of microvascular complications in type 2 diabetes mellitus, Sci Rep 6 (2016), 20032.

26.

Lerebours

Cizeron-Clairac

Susini

Vacher

Mouret-Fourme

Belichard

Brain

Alberini

J.L.

Spyratos

Lidereau

and Bieche

, miRNA expression profiling of inflammatory breast cancer identifies a 5-miRNA signature predictive of breast tumor aggressiveness, Int J Cancer 133 (2013), 1614–1623.

27.

Zhang

S.J.

Feng

J.F.

Wang

Guo

Y.W.

Ming

and Zhao

G.Q.

, miR-1303 targets claudin-18 gene to modulate proliferation and invasion of gastric cancer cells, Dig Dis Sci 59 (2014), 1754–1763.

28.

Liu

J.K.

Liu

H.F.

Ding

and Gao

G.D.

, Predictive value of microRNA let-7a expression for efficacy and prognosis of radiotherapy in patients with lung cancer brain metastasis: A case-control study, Medicine (Baltimore) 97 (2018), e12847.

29.

Feng

Jiang

Meng

and Shu

, A novel biomarker based on mirna to predict the prognosis of muscle-invasive bladder urothelial carcinoma, J Oncol 2019 (2019), 2654296.

30.

Naeli

Yousefi

Ghasemi

Savardashtaki

and Mirzaei

, The role of microRNAs in lung cancer: Implications for diagnosis and therapy, Curr Mol Med (2019).

31.

Chen

G.Y.

and Ruan

, Downregulation of microRNA-133b and its clinical value in non-small cell lung cancer, Onco Targets Ther 12 (2019), 9421–9434.

32.

Liu

Zhou

Jiang

Xiang

and Wang

, miR-1303 promotes the proliferation, migration and invasion of prostate cancer cells through regulating the Wnt/beta-catenin pathway by targeting DKK3, Exp Ther Med 18 (2019), 4747–4757.

33.

Xie

Gao

Xie

and Zhou

, miR-1303 promotes the proliferation of neuroblastoma cell SH-SY5Y by targeting GSK3beta and SFRP1, Biomed Pharmacother 83 (2016), 508–513.

34.

Luo

Chimge

N.O.

Zhou

Flodby

Castaldi

Firth

A.L.

Liu

Wang

Yang

Marconett

C.N.

Crandall

E.D.

Offringa

I.A.

Frenkel

and Borok

, CLDN18.1 attenuates malignancy and related signaling pathways of lung adenocarcinoma in vivo and in vitro , Int J Cancer 143 (2018), 3169–3180.

35.

Shimobaba

Taga

Akizuki

Hichino

Endo

Matsunaga

Watanabe

Yamaguchi

Yamazaki

Sugatani

and Ikari

, Claudin-18 inhibits cell proliferation and motility mediated by inhibition of phosphorylation of PDK1 and Akt in human lung adenocarcinoma A549 cells, Biochim Biophys Acta 1863 (2016), 1170–1178.

Upregulation of microRNA-1303 is a potential prognostic marker of non-small cell lung cancer

Abstract

BACKGROUND:

METHODS:

RESULTS:

CONCLUSION:

Keywords

1. Introduction

2. Materials and methods

2.1 Patients and tissue samples

2.2 Cell culture and transfection

2.4 Cell proliferation assay

2.5 Cell migration and invasion assays

Table 1 Correlation of the miR-1303 expression with clinical characteristics in NSCLC

3. Results

3.1 miR-1303 is upregulated in NSCLC tissues and cells

3.3 Increased expression of miR-1303 associates with prognosis in NSCLC

Footnotes

Conflict of interest

Supplementary data

References

Table 1
Correlation of the miR-1303 expression with clinical characteristics in NSCLC